$MTEM
Molecular Templates, Inc.

2015 Q2 Form 10-Q Financial Statement

#000156459015003127 Filed on April 30, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q4
Revenue $3.680M $3.680M $3.680M
YoY Change 0.0% 0.0% 14.64%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.480M $2.620M $2.620M
YoY Change 0.0% -0.38% 6.94%
% of Gross Profit
Research & Development $10.14M $10.68M $8.610M
YoY Change 17.05% 10.64% 0.94%
% of Gross Profit
Depreciation & Amortization $260.0K $240.0K $280.0K
YoY Change -23.53% -38.46% -33.33%
% of Gross Profit
Operating Expenses $12.62M $13.30M $11.23M
YoY Change 13.28% 8.21% 2.18%
Operating Profit -$8.941M -$9.615M
YoY Change 11.72%
Interest Expense $39.00K $33.00K $20.00K
YoY Change 30.0% -17.5% -33.33%
% of Operating Profit
Other Income/Expense, Net $596.0K -$1.572M $1.560M
YoY Change -91.06% -207.89% 578.26%
Pretax Income -$8.310M -$11.15M -$5.960M
YoY Change 979.22% 56.84% -20.64%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$8.306M -$11.15M -$5.964M
YoY Change 984.33% 56.9% -21.41%
Net Earnings / Revenue -225.71% -303.1% -162.07%
Basic Earnings Per Share -$0.12 -$0.17 -$0.09
Diluted Earnings Per Share -$0.12 -$0.17 -$0.12
COMMON SHARES
Basic Shares Outstanding 71.33M 66.73M
Diluted Shares Outstanding 72.82M 66.73M

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $67.00M $78.90M $58.60M
YoY Change 6.35% 9.58% -10.81%
Cash & Equivalents $10.57M $21.06M $8.391M
Short-Term Investments $56.50M $57.80M $50.20M
Other Short-Term Assets $1.500M $1.200M $800.0K
YoY Change -46.43% -7.69% -63.64%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $72.20M $82.10M $66.68M
YoY Change 3.0% 4.6% -22.47%
LONG-TERM ASSETS
Property, Plant & Equipment $424.0K $503.0K $557.0K
YoY Change -39.43% -20.41% -18.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $4.200M $0.00
YoY Change -100.0% -70.83% -100.0%
Other Assets $1.264M $1.201M $1.159M
YoY Change 5.33% 3.62% 9.44%
Total Long-Term Assets $1.654M $5.905M $1.716M
YoY Change -88.27% -63.51% -90.52%
TOTAL ASSETS
Total Short-Term Assets $72.20M $82.10M $66.68M
Total Long-Term Assets $1.654M $5.905M $1.716M
Total Assets $73.85M $88.01M $68.40M
YoY Change -12.29% -7.05% -34.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $635.0K $1.809M $2.074M
YoY Change -78.1% -54.84% 22.79%
Accrued Expenses $2.451M $4.196M $3.180M
YoY Change -74.73% 5.91% 0.6%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $25.53M $28.98M $25.97M
YoY Change -6.49% 2.81% -3.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $74.60M $78.90M $66.40M
YoY Change -12.34% -17.38% -34.0%
Total Long-Term Liabilities $74.60M $78.90M $66.40M
YoY Change -12.34% -17.38% -34.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $25.53M $28.98M $25.97M
Total Long-Term Liabilities $74.60M $78.90M $66.40M
Total Liabilities $100.2M $107.9M $92.37M
YoY Change -10.89% -12.75% -27.6%
SHAREHOLDERS EQUITY
Retained Earnings -$392.7M -$384.4M -$373.3M
YoY Change 7.14% 6.14%
Common Stock $366.4M $364.5M $349.3M
YoY Change 10.54% 6.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$26.30M -$19.89M -$23.98M
YoY Change
Total Liabilities & Shareholders Equity $73.85M $88.01M $68.40M
YoY Change -12.29% -7.05% -34.31%

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q4
OPERATING ACTIVITIES
Net Income -$8.306M -$11.15M -$5.964M
YoY Change 984.33% 56.9% -21.41%
Depreciation, Depletion And Amortization $260.0K $240.0K $280.0K
YoY Change -23.53% -38.46% -33.33%
Cash From Operating Activities -$15.87M -$3.840M -$10.13M
YoY Change 46.81% -188.07% 5.41%
INVESTING ACTIVITIES
Capital Expenditures -$20.00K $38.00K -$10.00K
YoY Change -86.67% 58.33% -80.0%
Acquisitions
YoY Change
Other Investing Activities $5.380M -$11.96M $6.880M
YoY Change -49.48% 129.12% -46.29%
Cash From Investing Activities $5.370M -$12.00M $6.870M
YoY Change -48.86% 129.01% -46.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $28.10M
YoY Change 8044.93%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 28.51M 410.0K
YoY Change -100.0% 8045.71% 241.67%
NET CHANGE
Cash From Operating Activities -15.87M -3.840M -10.13M
Cash From Investing Activities 5.370M -12.00M 6.870M
Cash From Financing Activities 0.000 28.51M 410.0K
Net Change In Cash -10.50M 12.67M -2.850M
YoY Change 3520.69% -2490.57% -186.89%
FREE CASH FLOW
Cash From Operating Activities -$15.87M -$3.840M -$10.13M
Capital Expenditures -$20.00K $38.00K -$10.00K
Free Cash Flow -$15.85M -$3.878M -$10.12M
YoY Change 48.69% -189.44% 5.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
557000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
13296000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8606000
CY2014Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
50209000
CY2015Q1 thld Accrued Clinical And Development Liabilities
AccruedClinicalAndDevelopmentLiabilities
8248000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8391000
CY2015Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1226000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
832000
CY2015Q1 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
57822000
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
28975000
CY2015Q1 us-gaap Liabilities
Liabilities
107898000
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
71000
CY2015Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
364471000
CY2015Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14722000
CY2015Q1 us-gaap Assets Current
AssetsCurrent
82104000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21063000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2074000
CY2015Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4196000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
66680000
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
503000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14722000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
63000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1159000
CY2014Q4 us-gaap Assets
Assets
68396000
CY2015Q1 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
4201000
CY2015Q1 us-gaap Other Receivables
OtherReceivables
1993000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-11154000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3180000
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
71334362
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1809000
CY2014Q4 thld Accrued Clinical And Development Liabilities
AccruedClinicalAndDevelopmentLiabilities
5998000
CY2015Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1201000
CY2015Q1 us-gaap Assets
Assets
88009000
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
243000
CY2014Q4 us-gaap Liabilities
Liabilities
92372000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71334362
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
71334362
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2014Q4 us-gaap Other Receivables
OtherReceivables
7248000
CY2015Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
20185000
CY2014Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
3961000
CY2015Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
58513000
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2015Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9615000
CY2015Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
33000
CY2014Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
40000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
349236000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-13000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62898233
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62898233
CY2014Q1 us-gaap Contracts Revenue
ContractsRevenue
3681000
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
1457000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2634000
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
12287000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10680000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2616000
CY2015Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
225000
CY2015Q1 us-gaap Contracts Revenue
ContractsRevenue
3681000
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-384416000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9653000
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
-19889000
CY2015Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-15000
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
88009000
CY2015Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-23976000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-373262000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
68396000
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
62194000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25974000
CY2014Q1 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2015Q1 us-gaap Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
0
CY2014Q1 us-gaap Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
0
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1572000
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1457000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-7109000
CY2015Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
CY2014Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-15000
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11156000
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7124000
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2015Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2015Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66732000
CY2014Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59303000
CY2015Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66732000
CY2014Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61300000
CY2015Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
239000
CY2014Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
390000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1421000
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1266000
CY2015Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-1532000
CY2015Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-5255000
CY2014Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-12902000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
436000
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-835000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-265000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2317000
CY2015Q1 thld Increase Decrease In Accrued Clinical And Development Liabilities
IncreaseDecreaseInAccruedClinicalAndDevelopmentLiabilities
2250000
CY2014Q1 thld Increase Decrease In Accrued Clinical And Development Liabilities
IncreaseDecreaseInAccruedClinicalAndDevelopmentLiabilities
-1952000
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1016000
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
801000
CY2015Q1 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
18000
CY2014Q1 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-47000
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3681000
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3681000
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3841000
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
4359000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
38000
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
24000
CY2015Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
32899000
CY2014Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
22349000
CY2015Q1 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
1997000
CY2014Q1 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
3109000
CY2015Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
18939000
CY2014Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
14024000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-12001000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-5240000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28514000
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
345000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
28514000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
345000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
12672000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-536000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7279000
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6743000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
50209000
CY2015Q1 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
CY2014Q1 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
-1757000
CY2015Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11154000
CY2014Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8866000
CY2015Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0
CY2014Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1997000
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
8300000
CY2015Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
8300000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28100000
CY2015Q1 thld Warrants Initial Exercise Price
WarrantsInitialExercisePrice
10.86
CY2015Q1 thld Warrant Maximum Adjusted Exercise Price
WarrantMaximumAdjustedExercisePrice
10.86
CY2015Q1 thld Warrant Minimum Adjusted Exercise Price
WarrantMinimumAdjustedExercisePrice
3.62
CY2015Q1 thld Warrant Term
WarrantTerm
P5Y
CY2015Q1 thld Warrants Twenty Day Vwap Exceeds
WarrantsTwentyDayVWAPExceeds
18.00
CY2014Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
3961000
CY2015Q1 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
14692000
CY2015Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
20185000
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1421000
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1266000
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
14600000
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M13D
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M13D
CY2015Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
24000
CY2014Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
36000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8168942
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1911500
CY2015Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
61456
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
25770
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9993216
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
9878829
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5521561
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.69
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.42
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.83
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.15
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.83
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.83
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.33
CY2015Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000
CY2015Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
62023000
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
50222000
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M11D
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y6M4D
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y3M22D
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8802913
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
8787468
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8010861
CY2014Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2015Q1 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
82037000
CY2014Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
58577000
CY2015Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
21000
CY2015Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
62038000
CY2015Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
17000
CY2014Q1 thld Weighted Average Maturity For Available For Sale Securities
WeightedAverageMaturityForAvailableForSaleSecurities
P4M27D
CY2015Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
34181000
CY2015Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
21000
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
691000
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
953000
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
238000
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1882000

Files In Submission

Name View Source Status
0001564590-15-003127-index-headers.html Edgar Link pending
0001564590-15-003127-index.html Edgar Link pending
0001564590-15-003127.txt Edgar Link pending
0001564590-15-003127-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
thld-10q_20150331.htm Edgar Link pending
thld-20150331.xml Edgar Link completed
thld-20150331.xsd Edgar Link pending
thld-20150331_cal.xml Edgar Link unprocessable
thld-20150331_def.xml Edgar Link unprocessable
thld-20150331_lab.xml Edgar Link unprocessable
thld-20150331_pre.xml Edgar Link unprocessable
thld-ex311_201503318.htm Edgar Link pending
thld-ex312_201503319.htm Edgar Link pending
thld-ex321_201503316.htm Edgar Link pending
thld-ex322_201503317.htm Edgar Link pending